Bioclassifier, NanoString to 'Decentralize' Breast Cancer Test as ARUP Preps qPCR Version

Bioclassifier has licensed to NanoString the rights to develop in vitro diagnostic and research products based on the so-called PAM50 gene signature and NanoString's nCounter platform. Meantime, ARUP Laboratories will next month launch a laboratory-developed qPCR test based on the signature.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.